Literature DB >> 20339375

Polymorphisms in CYP11B2 and CYP11B1 genes associated with primary hyperaldosteronism.

Guo-xi Zhang1, Bao-jun Wang, Jin-zhi Ouyang, Xi-yuan Deng, Xin Ma, Hong-zhao Li, Zhun Wu, Shuang-lin Liu, Hua Xu, Xu Zhang.   

Abstract

Several frequent polymorphisms in the CYP11B2 gene are suggested to be associated with essential hypertension and aldosterone secretion. In this study, we investigated the association of polymorphisms in CYP11B2 and CYP11B1 genes with the risk of primary hyperaldosteronism (PH). Three polymorphisms in the CYP11B2 gene (intron 2 conversion, rs1799998 and rs4539) and two polymorphisms in the CYP11B1 gene (rs6410 and rs6387) were analyzed in patients with PH and in the normal population. The rs6410 allelic frequencies in patients with aldosterone-producing adenoma (APA) and idiopathic hyperaldosteronism (IHA) were significantly different from those in controls at P=1.09 x 10(-5) and 0.015, respectively. There was a relative excess of AA homozygotes and AG heterozygotes of the rs6410 allele in the APA group as compared with the control group (P=2.19 x 10(-4)). There were significantly different genotypes, AA and AG, of the rs6410 allele between the patients with IHA and the controls only after adjustments for age, gender and body mass index (odds ratio (OR)=4.06, 95% confidence interval (CI) 1.31-12.66; OR=2.41, 95% CI 1.02-5.72). One susceptible haplotype, AAAWT, was identified to be significantly associated with APA (OR=1.44, 95% CI 1.19-1.76), and three susceptible haplotypes, AAAWT, AGGWT and AGAWC, were identified to be significantly associated with IHA (OR=1.55, 95% CI 1.23-1.96; OR=1.49, 95% CI 1.17-1.89; OR=1.40, 95% CI 1.04-1.88). In contrast, one protective haplotype, GGAWT, showed a significant difference between the patients with APA and controls (OR=0.73, 95% CI 0.55-0.97). Several haplotypes were associated with ARR in both the controls and cases. Our data demonstrated that there was a significant association between polymorphisms in the CYP11B2 and CYP11B1 genes and a genetic predisposition to PH. The association with IHA seemed closer compared with APA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20339375     DOI: 10.1038/hr.2010.21

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  6 in total

1.  Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study.

Authors:  James Brian Byrd; Richard J Auchus; Perrin C White
Journal:  J Investig Med       Date:  2015-10       Impact factor: 2.895

2.  Genetic variants in CYP11B1 influence the susceptibility to coronary heart disease.

Authors:  Xiaoli Huang; Yimin Cheng; Na Wang
Journal:  BMC Med Genomics       Date:  2022-07-13       Impact factor: 3.622

3.  Association of CYP11B2 polymorphisms with metabolic syndrome patients.

Authors:  Young Ree Kim; Sun Hyung Kim; Sung Ha Kang; Hyun Ju Kim; Mi Hee Kong; Seung Ho Hong
Journal:  Biomed Rep       Date:  2014-07-11

4.  Association Between the Polymorphism of Steroid Hormone Metabolism Genes and High-Altitude Pulmonary Edema in the Chinese Han Population.

Authors:  Hui Gao; Jin Xu; Qiang Ma; Feng Tang; Qin Ga; Yuhong Li; Wei Guan; Ri-Li Ge; Ying-Zhong Yang
Journal:  Int J Gen Med       Date:  2022-01-20

5.  Lifestage Sex-Specific Genetic Effects on Metabolic Disorders in an Adult Population in Korea: The Korean Genome and Epidemiology Study.

Authors:  Young-Sang Kim; Yon Chul Park; Ja-Eun Choi; Jae-Min Park; Kunhee Han; Kwangyoon Kim; Bom-Taeck Kim; Kyung-Won Hong
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

6.  Identification of new therapeutic targets by genome-wide analysis of gene expression in the ipsilateral cortex of aged rats after stroke.

Authors:  Ana-Maria Buga; Claus Jürgen Scholz; Senthil Kumar; James G Herndon; Dragos Alexandru; Gabriel Radu Cojocaru; Thomas Dandekar; Aurel Popa-Wagner
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.